HeartFlow's Plaque Analysis Leading The Way: 95% Accuracy vs Invasive Imaging In Newly Published REVEALPLAQUE Study
15 mai 2024 12h00 HE
|
HeartFlow Holding, Inc.
MOUNTAIN VIEW, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- HeartFlow, Inc., a leader in non-invasive artificial intelligence (AI) heart care solutions, today announced that the data from its...
HeartFlow Announces Revolutionary Five-Year Data Demonstrating a 63 Percent Mortality Reduction with FFRCT-Guided Care in PAD Patients
08 mai 2024 12h00 HE
|
HeartFlow Holding, Inc.
MOUNTAIN VIEW, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- In a groundbreaking development, a study published in the Journal of Vascular Surgery reveals for the first time that coronary CTA (CCTA) with...
HeartFlow Announces Publication of 10-year Follow-Up Data from the DISCOVER-FLOW Study in the Journal of Cardiovascular Computed Tomography
12 mars 2024 09h00 HE
|
HeartFlow Holding, Inc.
HeartFlow's non-invasive AI driven FFRCT predicts patient outcomes as effectively as the gold-standard invasive FFR out to 10 years MOUNTAIN VIEW, Calif., March 12, 2024 (GLOBE NEWSWIRE) --...
Curonix Partners with Sure Med Compliance to Expand PNS Clinical Evidence
18 janv. 2024 08h00 HE
|
Curonix LLC
Curonix Partners with Sure Med Compliance to Expand PNS Clinical Evidence
TCT 2023: HeartFlow Presents Clinical Data Featuring First Solution Offering Lesion-Specific Insights
25 oct. 2023 11h00 HE
|
HeartFlow Holding, Inc.
New Clinical Data Support Use of Lesion-Specific FFRCT for Diagnosis and Treatment of Patients With Coronary Artery Disease
Processa Pharmaceuticals To Present an Update on Its Future Therapeutic Focus and Strategy at the Biotech Showcase on January 11, 2023.
04 janv. 2023 08h30 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), Dr. David Young, Processa Pharmaceuticals, CEO will present an update on Processa’s future therapeutic...
Processa Pharmaceuticals CEO Dr. David Young Issues Letter to Shareholders Providing Outlook for 2022
26 janv. 2022 08h15 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical stage company developing drugs for patients who have unmet...
Real-World Evidence (RWE) Solutions Market Worth $4.4 Billion by 2028 - Exclusive Report by Meticulous Research®
17 nov. 2021 10h45 HE
|
Meticulous Market Research Pvt. Ltd.
Redding, California, Nov. 17, 2021 (GLOBE NEWSWIRE) -- According to a new market research report titled “RWE Solutions Market by Component (Datasets [Clinical, Claims, Pharmacy, Integrated],...
Processa Pharmaceuticals to Present at “Zooming with LD Micro” Virtual Investor Event on July 29, 2021 at 12:00 p.m. ET
27 juil. 2021 08h30 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, July 27, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced today that it will be presenting at the upcoming “Zooming with LD Micro” virtual investor event...
Processa Pharmaceuticals to Present at LD Micro Virtual Investor Conference on June 9, 2021, at 1:30pm ET
07 juin 2021 16h05 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, June 07, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve...